<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168068">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01776099</url>
  </required_header>
  <id_info>
    <org_study_id>DiNA-1</org_study_id>
    <nct_id>NCT01776099</nct_id>
  </id_info>
  <brief_title>Diabetes Nutrition Algorithms - Galactose- and Fiber-induced Metabolic Improvement in the Dietetic Treatment of Type 2 Diabetes</brief_title>
  <acronym>DiNA</acronym>
  <official_title>Diabetes Nutrition Algorithms - Galactose- and Fiber-induced Metabolic Improvement in the Dietetic Treatment of Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German Institute of Human Nutrition</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deutsche Diabetes Gesellschaft (German Diabetes Society)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Firma Rettenmeier &amp; Söhne (Company)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>German Institute of Human Nutrition</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In animal models and retrospective studies, certain food components such as sugars and fiber
      have been detected as potential agents to influence development and progress of type 2
      diabetes.

      The DiNA study prospectively investigates, if non-soluble non-fermentable fibers (vs.
      soluble ones) and galactose (vs. palatinose) are capable to improvement metabolic parameters
      in patients with long-term type 2 diabetes and intensive insulin treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>metabolic improvement of type 2 diabetes</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>metabolic improvement of type 2 diabetes, as to be shown via hyperinsulinemic-euglycaemic clamp, mixed-meal test and daily demand of insulin units</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>pure galactose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 grams of galactose, three times a day with the main meals, duration: 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pure palatinose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5 grams of palatinose, three times a day with the main meals, duration: 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>soluble non-fermentable fibers</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5 grams of soluble non-fermentable fibers, three times a day with the main meals, duration: 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-soluble non-fermentable fibers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 grams of non-soluble non-fermentable fibers, three times a day with each main meal, duration: 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dietary supplement (4 arms, 2 active, 2 placebo)</intervention_name>
    <arm_group_label>pure galactose</arm_group_label>
    <arm_group_label>pure palatinose</arm_group_label>
    <arm_group_label>soluble non-fermentable fibers</arm_group_label>
    <arm_group_label>non-soluble non-fermentable fibers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 2 diabetes, insulin-dependent

          -  high insulin resistance

        Exclusion Criteria:

          -  accompanying disease, medication or metabolic disorder, which interact with glucose
             metabolism or eating behavior (e.g. renal insufficiency, major cardial insuffiency,
             untreated hypothyreosis, corticoid treatment, depression and other psychiatric
             disorders...)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas F.H. Pfeiffer, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>German Institute for Human Nutrition</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefan Kabisch</last_name>
    <phone>030 8445 3474</phone>
    <email>stefan.kabisch@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gabriele Klampke</last_name>
    <email>diabetes@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charité-Klinikum Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Kabisch</last_name>
      <phone>030 8445 3474</phone>
      <email>stefan.kabisch@charite.de</email>
    </contact>
    <contact_backup>
      <email>diabetes@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Stefan Kabisch</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 23, 2013</lastchanged_date>
  <firstreceived_date>January 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>German Institute of Human Nutrition</investigator_affiliation>
    <investigator_full_name>Prof. Dr. med. Andreas F. H. Pfeiffer</investigator_full_name>
    <investigator_title>Director of the Department for Clinical Nutrition</investigator_title>
  </responsible_party>
  <keyword>type 2 diabetes</keyword>
  <keyword>nutrition</keyword>
  <keyword>fibers</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
